About: Convalescent plasma therapy in patients with COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Convalescent plasma therapy in patients with COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Convalescent plasma therapy in patients with COVID‐19
Creator	Baştürk, Abdülkadir Dal, Sinan Dal, Tuba Erkurt, Ali Fevzi Altuntaş, \| Geno Glu, Yi Glu, Hacıbekiro Glu, Namdaro Gçe Nur, Tu Ilhami Berber, \| Mehmet, \| Serdal Korkmaz, \| Sinem, \| Tuba, \| Turgut, Burhan Ulas, Turgay
Source	Medline; PMC; WHO
abstract	There are currently no licensed vaccines or therapeutics for COVID‐19. Anti‐SARS CoV‐2 antibody‐containing plasmas, obtained from the recovered individuals who had confirmed COVID‐19, have been started to be collected using apheresis devices and stored in blood banks in some countries in order to administer to the patients with COVID‐19 for reducing the need of intensive care and the mortality rates. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVID‐19. CP may be an adjunctive treatment option to the anti‐viral therapy. The protective effect of CP may continue for weeks and months. After the assessment of the donor, 200‐600 mL plasma can be collected with apheresis devices. The donation interval may vary between countries. Even though limited published studies are not prospective or randomized, until the development of vaccines or therapeutics, CP seems to be a safe and probably effective treatment for critically ill patients with COVID‐19. It could also be used for prophylactic purposes but the safety and effectiveness of this approach should be tested in randomized prospective clinical trials.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1002/jca.21806
bibo:pmid	32643200
has license	no-cc
sha1sum (hex)	43eb8c64089f303d53f8928e952914396e86ea22
schema:url	https://doi.org/10.1002/jca.21806
resource representing a document's title	Convalescent plasma therapy in patients with COVID‐19
has PubMed Central identifier	PMC7361338
has PubMed identifier	32643200
schema:publication	J Clin Apher
resource representing a document's body	covid:43eb8c64089f303d53f8928e952914396e86ea22#body_text
is schema:about of	named entity 'therapeutics' named entity 'LICENSED' named entity 'MORTALITY RATES' named entity 'ISSUES' named entity 'PATIENTS' named entity 'ORDER TO ADMINISTER' named entity 'ADJUNCTIVE TREATMENT' named entity 'ANTIBODY' named entity 'COVID-19' named entity 'individuals' named entity 'patients' named entity 'blood banks' named entity 'COVID-19' named entity 'SARS CoV' named entity 'blood banks' named entity 'COVID-19' named entity 'anti-viral therapy' named entity 'mortality rates' named entity 'Convalescent plasma therapy' named entity 'COVID' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'blood oxygen saturation' named entity 'RNA' named entity 'RT-PCR' named entity 'SARS-CoV-2' named entity 'infection' named entity 'apheresis' named entity 'intravenous immunoglobulin' named entity 'ribavirin' named entity 'apheresis' named entity 'transfusion' named entity 'WHO' named entity '1:160' named entity 'comorbidities' named entity 'antibody' named entity 'SARS-CoV-2' named entity 'titer' named entity 'COVID-19' named entity 'American Food and Drug Administration' named entity 'Nobel Prize' named entity 'transfusion' named entity 'immunological' named entity 'ABO blood group' named entity 'global outbreak' named entity 'Respiratory Syncytial Virus' named entity 'antibodies' named entity 'randomized controlled clinical trials' named entity 'COVID-19' named entity '1:160' named entity 'seroconversion' named entity 'observational studies' named entity '2019-nCoV' named entity 'pneumonia' named entity 'antibody titer' named entity 'chronic obstructive pulmonary disease' named entity 'RNA' named entity 'clinical research' named entity 'SARS-CoV-2' named entity 'antibody' named entity 'apheresis' named entity 'prophylactic' named entity 'IgA' named entity 'TRALI' named entity 'clinical symptoms' named entity 'solvent'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software